ICSA 2020 Applied Statistics Symposium

Virtual Panels on Leadership and Big Data

12:20 PM to 1:50 PM, U.S. Central Time (CT), December 14 and 15, 2020

The 2020 ICSA Applied Statistics Symposium (https://symposium2020.icsa.org), held virtually from December 13 to 16, 2020, is the 29th annual symposium for the International Chinese Statistical Association (ICSA). The conference theme is *Advancing Statistics for Data Intelligence*.

Panel 1: *Leadership in Statistics and Data Science*, Noon, CT, December 14, 2020

Panelists: Haoda Fu, Eli Lilly and Company; Lauren Lee, Pfizer Inc; Mengling Liu, NYU Langone Health; Jie Tang, Lotus Clinical Research LLC.; Yuanjia Wang, Mailman School of Public Health, Columbia University; Tian Zheng, Columbia University; Richard C. Zink, Lexitas Pharma Services.
Moderator: Kelly H. Zou, Viatris.

Bill Gates once said: "As we look ahead into the next century, leaders will be those who empower others." This rings a bell not only when we look into the distant future but also meet global challenges arising from a pandemic at present. Leaders have multiple characteristics. According to Forbes, key elements are: coaching, not directing; being adept; respect; being a master communicator. This panel session discusses such elements and beyond with a special focus on statistics and data science. Tips for being a good leader in a diverse and inclusive organization are provided using the panelists' own experience and observation. Finally, mentorship is emphasized to maximize future statistics and data science talents both now and well into the future.

Panel 2: *Real-World Evidence to Advance Healthcare*, Noon, CT, December 15, 2020

Panelists: Joseph P. Cook, Viatris; Aaron Galaznik, Acorn AI, Medidata Solutions; Joseph Imperato, Viatris; Max Ma, Johnson & Johnson; Jun Su, Astellas; May Yamada-Lifton, SAS.
Moderator: Kelly H. Zou, Viatris.

The 21st Century Cares Act provided a definition of real-world evidence (RWE) and codified its use in the United States regulatory framework of marketing authorizations. Real-world data (RWD) can come from a variety of sources, e.g., claims, electronic health records, biobanks, genomics, and imaging modalities, particularly digital data through eHealth and mHealth. As a consequence of the current pandemic, digital innovation, patient preference, and electronic patient reported outcomes (ePROs) may increasingly be used. RWE may help identify patients for randomized clinical trials (RCTs), optimize RCT design, and help optimize evidence packages to accelerate the approval and reimbursement processes. Recent events have pushed innovation in the use of RWD to maximize the value of RWE in an era of big data, data science and artificial intelligence.

If you have any questions, please send an email to symposium2020@icsa.org.